X0306 4 2022-11-15 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856081 Virani Shafique C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 Chief Business Officer Class A Common Stock 2022-11-15 4 F 0 613 11.86 D 88160 D Class A Common Stock 2022-11-15 4 M 0 5000 2.22 A 93160 D Class A Common Stock 2022-11-15 4 S 0 5059 12.70 D 88101 D Class A Common Stock 2022-11-15 4 S 0 4941 11.9153 D 83160 D Stock Option (Right to Buy) 2.22 2022-11-15 4 M 0 5000 0.00 D 2030-03-20 Class A Common Stock 5000 646955 D Stock Option (Right to Buy) 11.40 2032-02-04 Class A Common Stock 0 80450 D Stock Option (Right to Buy) 11.40 2022-02-04 2032-02-04 Class A Common Stock 0 5436 D Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.34 to $12.32 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Jonathan Golightly, attorney-in-fact 2022-11-17